Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 100.16M P/E - EPS this Y 52.00% Ern Qtrly Grth -
Income -59.05M Forward P/E -1.72 EPS next Y 19.40% 50D Avg Chg -5.00%
Sales 12.17M PEG -0.02 EPS past 5Y 19.36% 200D Avg Chg -11.00%
Dividend N/A Price/Book N/A EPS next 5Y 30.00% 52W High Chg -82.00%
Recommedations 1.00 Quick Ratio 1.11 Shares Outstanding 22.05M 52W Low Chg 53.00%
Insider Own 43.52% ROA -73.60% Shares Float 10.98M Beta 0.54
Inst Own 21.47% ROE - Shares Shorted/Prior 387.34K/373.71K Price 6.89
Gross Margin 18.59% Profit Margin - Avg. Volume 26,734 Target Price 1.50
Oper. Margin -347.69% Earnings Date Aug 8 Volume 18,126 Change -1.29%
About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics, Inc. News
05/09/24 Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript
05/09/24 Q1 2024 Accelerate Diagnostics Inc Earnings Call
05/09/24 Accelerate Diagnostics Inc (AXDX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
05/08/24 Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
05/08/24 Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results
05/02/24 Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
05/02/24 Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.
04/02/24 Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript
03/29/24 Q4 2023 Accelerate Diagnostics Inc Earnings Call
04:45 PM Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
03:05 PM Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
03/07/24 Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
01/19/24 Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
01/16/24 Accelerate Diagnostics Announces Launch of Proposed Public Offering
01/07/24 Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
11/29/23 Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
07:50 AM Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
11/27/23 Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
11/22/23 Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11/11/23 Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript
AXDX Chatroom

User Image WhackaMole Posted - 1 hour ago

$AXDX I recall the last $15M raise was at $1.5 with warrants at $1.65. We are basically at the stock issue price. Would be great to see a major move through the warrant strikes as well.

User Image JPecton Posted - 3 hours ago

$AXDX nice set up

User Image Esau815 Posted - 4 hours ago

$AXDX MicroGuy is a smart guy who knows a lot of stuff. I'm not trying to pick a fight with him. Some things that can't be debated: 1. Phillips said at last conference call that preclinical was up and running on one site and that the second site was delayed. He said that Clinical would start before Q3. 2. Obviously, they have not announced preclinical data while it's ongoing. 3. Most importantly: a. BDX knows more than I do. My guess is that they know more than Micro Guy. b. BDX is the one who needs a "workflow platform" to compete against BM. c. BDX is the one who JOINTLY PRESENTED at ECCMID. d. Roche also voiced their support during this presentation. 4. Will agree with MicroGuy that if Wave crashes and burns on preclinical that we're at zero.

User Image Esau815 Posted - 1 day ago

$AXDX Healthy debate: 1. Micro Guy--you're too smart to say, "We don't know anything about Wave". There are many decks describing this Rapid AST device that combines isolates and PBC. 2. As per demand. You guys are looking at this wrong. There's a race on to create moat likes "workflow platforms". BioMereiux is on that path. With Arc at the front end and Wave at the back end and Bruker Maldi Tof in the middle that's what BDX is likely looking for. 3. Roche and BDX need rapid AST--and likely Arc--to create their moat like dependency. Time if of the essence--from both AXDX and BDX perspectives. As per timing? Phillips has said Clinical Trials will start by July 1. Obviously, delays can occur. 4. AXDX stock virtually doubled last week. I know nothing more than the public. But it sure seems that something either on the preclinical front or strategic front is afoot.

User Image hitmongreen Posted - 1 day ago

$AXDX run here has started

User Image Esau815 Posted - 2 days ago

$AXDX To Tigereye: 1. It's extremely difficult to determine "what's the best avenue for shareholders". It all depends upon whether one or more companies want Wave. 2. AXDX does NOT have a lot of money. Thus, if interest is limited--and it might be--then we'll be lucky to get whatever we can. If Roche, Danaher, others are interested--then there's a very high price that might be had. As of now? There's no public way of knowing. 3. The math is kind of simple. The converts get the first $70MM and any upside above $7.20 per share. If the share price is between $1.65 and above there are 29MM non convert shares. In a hypothetical $220MM deal? Common would get about $5 per share. Would be thrilled if that occurred.

User Image Dawgshepherd Posted - 3 days ago

$AXDX I am so excited to be up .09 cents. I knew this stock would someday reward me. Now if it would just go back to 30.00 bucks......

User Image Esau815 Posted - 3 days ago

$AXDX If they blow threw $1.65--and that's a big if--the company will get additional warrant money runway. Though I don't know how many would actually exercise at sub $2 prices. The bigger concern is that there are 6MM shares that will likely be sold as the warrant holders get their money back and keep the warrants for the upside. I was surprised by this week's action. AXDX blew through its NASDAQ listing problem by soaring through $1. Micro and I might disagree about timing vis a vis clinical and pre clinicall and a suitor walking in. But the story hasn't changed. The only questions: Can they score a deal for Wave and if so how much cash can they get?

User Image Zedemel Posted - 3 days ago

$AXDX strange stock.... nothing else to say 😀

User Image vpalani Posted - 3 days ago

$AXDX $2 is incoming 📈🍀

User Image Esau815 Posted - 4 days ago

$AXDX Jack's additional investment is basically one month's runway. Not that big a deal. The critical issues are the progress of the preclinical trials as well as of course strategic partnership discussions. As I said earlier, I certainly don't know what's going on. But it sure seems like others have information that I don't.

User Image WhackaMole Posted - 4 days ago

$AXDX BTW, with Jack’s previously committed purchases - that he delayed 3 times, was the timing consistent with the commitment or did it happen a bit earlier?

User Image Esau815 Posted - 4 days ago

$AXDX There's a big over hang at $1.65. That's where the warrants are at. If we burst through that? Without a deal announced? That would be something.

User Image duuuuuubs Posted - 4 days ago

$AXDX glad I sold at 1.09 🤦🏻‍♂️

User Image Zedemel Posted - 4 days ago

$AXDX insiders must declare their purchases. These are "little insiders" of Axdx or Bd, or..... i dont know....the next meme stock?.... dont know. We will see soon. For sure, here with little volumes make move the price fastly.

User Image PLATINUM_TRADES Posted - 4 days ago

$AXDX I told u where it was going ! If you're with me... You banking 🐐🐐🐐🐐

User Image JPecton Posted - 4 days ago

$AXDX Buying heavily here

User Image Esau815 Posted - 4 days ago

$AXDX Your reporter Esau is completely in the dark on this one. If the SEC were to say, "What did Esau know and when did he know it?" the answer would be, "I have ZERO facts as to why AXDX is up 13%--soaring over $1 Nasdaq barrier--while the Dow is down 600 and the XBI is getting slaughtered. I've seen instances like this when word starts to leak out about a deal and the pattern here seems to mirror that. Thinly traded. But the ask continually gets hit. Anyone with an internet connection knows that they are working on a deal to happen "mid year". But Mr. Market usually rewards real deals and "potential" is best discussed in a Fiona Apple song. Bottom line: #1 I don't know anything. #2. It sure seems like someone knows more than I do.

User Image PLATINUM_TRADES Posted - 4 days ago

$AXDX it's a slow one but those adds were delicious! 🐐🐐

User Image Esau815 Posted - 5 days ago

$AXDX The "director filing" was nothing more than a Schuler filing from a commitment made many months ago that he buy stock at $1.73. Hard to believe that this is what's the cause behind the recent share price bursting through $1. My guess is that Phillips is indeed truthful and that a strategic partnership of some sort regarding Wave will be announced by "mid year".

User Image HeyDuggee Posted - 5 days ago

$MDAI is a gamechanging AI technology that provides immediate wound healing prediction using its proprietary and patented technology. • Breakthrough technology with no competitors. • $250m total US Government contracts awarded – NON DILUTIVE FUNDING! • Under $30m market cap • Around 52% of shares held by insiders. • Around 21% of shares held by institutions. • LOW FLOAT • Deploying their main product, DeepView®, in the UK. Initial feedback from the medical professionals has been excellent. • Initiating commercial transactions in the UK in 2nd half of this year. • In the U.S, total medical costs for diabetic foot disease ranges from 9 to 13 billion annually. Diabetic Foot Ulcers (DFU) is only one of the current clinical applications. • 10 US patents and 10 foreign patents (more in the pipeline) • Clinical applications possibly be expanded to other medical programs. $OWLT $AKLI $AXDX DYOR - share price won’t be this cheap for too long.

User Image PLATINUM_TRADES Posted - 5 days ago

$AXDX 1.5 mill acquired by the director??? Hmmm 🥊🥊🥊🥊

User Image Fullratio Posted - 5 days ago

$AXDX price to sales (P/S) is 96% less than its 5-year quarterly average of 41.6 and 66% less than its last 4 quarters average of 5.0: https://fullratio.com/stocks/nasdaq-axdx/accelerate-diagnostics

User Image Esau815 Posted - 6 days ago

$AXDX Nothing is going to make this stock explode unless they announce a very advantageous strategic partnership.

User Image PLATINUM_TRADES Posted - 6 days ago

$AXDX adds! $1.25 soon? Seriously? You don't think this will explode... Looks setup to me..... I'll take it 🥊🥊🥊🥊

User Image Esau815 Posted - 6 days ago

$AXDX Obviously, I'm in the dark here and not in Tucson or Indianapolis (Roche) or Maryland (BDX). But volume was significant. I was expecting a huge afternoon push to drive it under $1 for the shorts to preserve their Nasdaq listing issue. But if anything the opposite happened. Micro brings good info to the table. But at the end of the day, the driving force of the shares will be the strategic partnership--either outright purchase or distribution agreement. Ideally, they'd have Clinical Trial data in hand but at this point it looks like Pre Clinical will suffice. And there's no law that says a deal can't happen before that. It's "Show me the money" time---very, very soon.

User Image Zedemel Posted - 6 days ago

$AXDX 597000 volume

User Image Aigner_Andreas Posted - 6 days ago

TF BUY $AXDX at 1.08 : 1 NanoCap -98% Shp 2.36 S 1.92 N 0.59 RSI 66.33% SRSI 100% ADXR 16.59 #stocks #trading #finance #market

User Image PLATINUM_TRADES Posted - 6 days ago

$AXDX small floater with big volume hasn't recovered since it fell off from around $4.00 but looks like it's time for change as this could go back to $2.00 area soon imo this break signals good things looks like🥊🥊🥊🥊

User Image mikedaley Posted - 6 days ago

$AXDX What’s up with these purchases of Restricted stocks units for zero cost ?

Analyst Ratings
Craig-Hallum Hold Apr 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Phillips Jack Chief Executive Offi.. Chief Executive Officer Dec 13 Sell 4.39 739 3,244 59,535 12/14/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Dec 13 Option 0 1,721 60,274 12/14/23
Patience David Chief Financial Offi.. Chief Financial Officer Dec 13 Sell 4.39 97 426 8,931 12/14/23
Patience David Chief Financial Offi.. Chief Financial Officer Dec 13 Option 0 331 9,028 12/14/23
Patience David Chief Financial Offi.. Chief Financial Officer Oct 13 Sell 5.83 96 560 8,463 10/16/23
Patience David Chief Financial Offi.. Chief Financial Officer Oct 13 Option 0 331 8,559 10/16/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Oct 13 Sell 5.83 734 4,279 57,576 10/16/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Oct 13 Option 0 1,721 58,310 10/16/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Aug 13 Sell 6.8 751 5,107 55,600 08/15/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Aug 13 Option 0 1,722 56,351 08/15/23
Patience David Chief Financial Offi.. Chief Financial Officer Aug 13 Sell 6.8 95 646 7,993 08/15/23
Patience David Chief Financial Offi.. Chief Financial Officer Aug 13 Option 0 331 8,088 08/15/23
Patience David Chief Financial Offi.. Chief Financial Officer Jul 13 Sell 6.9 92 635 7,757 07/17/23
Patience David Chief Financial Offi.. Chief Financial Officer Jul 13 Option 0 330 7,849 07/17/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Jul 13 Sell 6.9 729 5,030 54,629 07/17/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Jul 13 Option 0 1,722 55,358 07/17/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Jun 22 Sell 0.71 27,262 19,356 536,362 06/26/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Jun 22 Option 0 62,160 563,624 06/26/23
Mertz Larry Michael Chief Technology Off.. Chief Technology Officer May 22 Sell 0.72 3,480 2,506 525,695 05/24/23
Mertz Larry Michael Chief Technology Off.. Chief Technology Officer May 22 Option 0 12,836 526,464 05/24/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer May 15 Sell 0.69 7,940 5,479 492,638 05/16/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer May 15 Option 0 17,217 500,578 05/16/23
Patience David Chief Financial Offi.. Chief Financial Officer May 15 Sell 0.69 1,222 843 73,170 05/16/23
Patience David Chief Financial Offi.. Chief Financial Officer May 15 Option 0 3,309 74,392 05/16/23
Patience David Chief Financial Offi.. Chief Financial Officer Apr 13 Option 0 3,309 72,230 04/17/23
Patience David Chief Financial Offi.. Chief Financial Officer Apr 13 Sell 0.65 1,147 746 71,083 04/17/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Apr 13 Sell 0.65 7,444 4,839 483,361 04/17/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Apr 13 Option 0 17,216 490,805 04/17/23
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Mar 08 Sell 0.47 62,778 29,506 137,640 03/13/23
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Mar 08 Option 0 123,600 200,418 03/13/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Mar 08 Sell 0.47 155,635 73,148 463,823 03/13/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Mar 08 Option 0 350,000 619,458 03/13/23
Mertz Larry Michael Chief Technology Off.. Chief Technology Officer Mar 02 Sell 0.49 33,401 16,366 516,339 03/06/23
Mertz Larry Michael Chief Technology Off.. Chief Technology Officer Mar 02 Option 0 116,329 549,740 03/06/23
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Feb 13 Sell 0.6 4,823 2,894 76,818 02/15/23
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Feb 13 Option 0 9,439 81,641 02/15/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Feb 13 Option 0 17,216 278,059 02/15/23
Phillips Jack Chief Executive Offi.. Chief Executive Officer Feb 13 Sell 0.6 8,601 5,161 269,458 02/15/23
Mertz Larry Michael Chief Technology Off.. Chief Technology Officer Aug 30 Buy 1.60 50,000 80,000 433,411 08/30/22
Mertz Larry Michael Chief Technology Off.. Chief Technology Officer Aug 22 Buy 1.35 51,749 69,861 383,411 08/22/22
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Aug 22 Buy 1.39 5,000 6,950 67,493 08/22/22
Phillips Jack Chief Executive Offi.. Chief Executive Officer Jun 22 Option 0 62,160 270,233 06/24/22
Phillips Jack Chief Executive Offi.. Chief Executive Officer Jun 22 Sell 0.91 28,198 25,660 242,035 06/24/22
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Apr 26 Option 0 57,736 92,408 04/28/22
REICHLING STEVEN Chief Financial Offi.. Chief Financial Officer Apr 26 Sell 0.98 29,915 29,317 62,493 04/28/22
Phillips Jack Chief Executive Offi.. Chief Executive Officer Apr 26 Option 0 168,396 291,781 04/28/22
Phillips Jack Chief Executive Offi.. Chief Executive Officer Apr 26 Sell 0.98 83,708 82,034 208,073 04/28/22
Price Ron Head of Commercial O.. Head of Commercial Operations Apr 21 Option 0 40,755 55,682 04/25/22
Price Ron Head of Commercial O.. Head of Commercial Operations Apr 21 Sell 0.98 15,072 14,771 40,610 04/25/22
Phillips Jack Chief Executive Offi.. Chief Executive Officer Feb 01 Option 0 10,000 127,038 02/07/22